Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTELLAR XR vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
FDA-approved as monotherapy or adjunctive therapy for partial-onset seizures in adults and children aged 4 years and older,Off-label: bipolar disorder, trigeminal neuralgia, diabetic neuropathy
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal half-life approximately 20-30 hours in adults; after multiple doses, effective half-life is about 24 hours, allowing once-daily dosing. Steady state reached in 4-5 days.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Oxcarbazepine is extensively metabolized by cytosolic enzymes to the active metabolite MHD (10,11-dihydro-10-hydroxy-carbazepine). MHD undergoes further glucuronidation and is excreted renally. Minor metabolism via CYP450 enzymes (CYP3A4/5) accounts for a small fraction.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (70-80% as unchanged drug and metabolites) and fecal (20-30% via biliary excretion).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 40% bound to serum proteins, mainly albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.7-0.8 L/kg, indicating distribution into total body water and some tissue binding.
4-6 L/kg; large Vd indicates extensive tissue distribution
Extended-release: 80-90% relative to immediate-release. No significant food effect.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For creatinine clearance <30 m L/min: start at 150 mg twice daily (300 mg/day) and titrate slowly; patients with ESRD on dialysis: not recommended due to lack of data.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required. Severe hepatic impairment (Child-Pugh C): not studied; use with caution.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For patients 6 years and older: oxcarbazepine XR (OXTELLAR XR) is not approved; use immediate-release oxcarbazepine based on weight: 8-10 mg/kg/day initially, titrated over 2 weeks to target 300-600 mg/day for 20-29 kg, 600-900 mg/day for 29.1-39 kg, 900-1200 mg/day for >39 kg. Not recommended under 6 years.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Elderly patients may have reduced clearance; start at 150 mg twice daily (300 mg/day) and titrate slowly. Monitor for hyponatremia, especially in those on diuretics or with low baseline sodium.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Hyponatremia (sodium <125 mmol/L) can occur, especially in elderly or patients on other hyponatremic drugs; monitor sodium levels,Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue if rash develops,Suicidal behavior and ideation: monitor for worsening depression or suicidal thoughts,Dizziness, somnolence, ataxia: caution with activities requiring alertness,Multi-organ hypersensitivity reactions: discontinue if suspected,Withdrawal seizures: do not discontinue abruptly,Hematologic effects: rare agranulocytosis, aplastic anemia; monitor CBC if symptoms occur
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to oxcarbazepine or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Take with or without food consistently. Avoid grapefruit juice (may affect drug metabolism). No specific food restrictions but maintain consistent dietary habits to avoid fluctuations in absorption.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Oxcarbazepine, the active moiety in Oxtellar XR, is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and cardiovascular anomalies, when used during the first trimester. In the second and third trimesters, use may be associated with adverse neurodevelopmental outcomes. The risk is dose-dependent and may be potentiated by concomitant antiepileptic drugs.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Oxcarbazepine and its active metabolite (MHD) are excreted into breast milk. The infant's plasma MHD concentration is approximately 10-30% of the maternal level, with M/P ratio for MHD estimated at 0.5-1.0. While generally considered compatible with breastfeeding, monitor the infant for drowsiness, poor feeding, and rash.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Due to increased clearance and volume of distribution during pregnancy, especially in the third trimester, dosage increments may be necessary to maintain therapeutic levels. Monitoring MHD trough concentrations and adjusting dose to achieve target levels is recommended. Postpartum, dose reduction may be required.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Oxtellar XR (oxcarbazepine extended-release) is a voltage-gated sodium channel blocker used as adjunctive therapy for partial-onset seizures. Titrate slowly to minimize CNS side effects; start at 600 mg/day and increase weekly by 300 mg/day to target 1200-2400 mg/day. Monitor serum sodium levels frequently, especially in elderly or patients on other hyponatremic drugs. Dose adjustments needed in renal impairment (Cr Cl <30 m L/min: start at 300 mg/day). A 20% increase in dose may be required when switching from immediate-release oxcarbazepine. CYP3A4/5 inducer; may reduce efficacy of hormonal contraceptives.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take once daily with or without food; swallow tablet whole, do not crush or chew.,Report symptoms of hyponatremia: nausea, headache, confusion, lethargy, weakness.,May cause dizziness, somnolence, or ataxia; avoid driving until effects known.,Serious skin reactions (SJS/TEN) possible; seek immediate care for rash or blisters.,Hormonal contraceptives may be less effective; use additional non-hormonal method.,Do not stop abruptly; taper to avoid withdrawal seizures.,Avoid alcohol; may worsen CNS depression.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTELLAR XR vs ABSTRAL, answered by our medical review team.
OXTELLAR XR is a Opioid Analgesic that works by Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTELLAR XR and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTELLAR XR is: Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTELLAR XR and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTELLAR XR is classified as Category C. Oxcarbazepine, the active moiety in Oxtellar XR, is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.